Verastem (VSTM) Net Cash Flow Growth (3y) (2014 - 2026)
Powered by 
Analysis
Verastem (VSTM) Net Cash Flow Growth (3y) (2014 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -8.34% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 36.60% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -35.85% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 106.37% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 67.39% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 4.55% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 52.78% |
| 10 | Verastem | 814.94 Mn | 678.59 Mn | 36.32 Mn | -32.78% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -32.78% |
| Mar 31, 2026 | -54.91% |
| Dec 31, 2025 | 174.74% |
| Sep 30, 2025 | -47.47% |
| Jun 30, 2025 | 39.39% |
| Mar 31, 2025 | 4.17% |
| Dec 31, 2024 | -99.62% |
| Sep 30, 2024 | 261.64% |
| Jun 30, 2024 | 27.99% |
| Mar 31, 2024 | 28.24% |
| Dec 31, 2023 | 49.54% |
| Sep 30, 2023 | -58.09% |
| Jun 30, 2023 | 120.00% |
| Mar 31, 2023 | -36.92% |
| Dec 31, 2022 | 47.49% |
| Sep 30, 2022 | 52.64% |
| Jun 30, 2022 | -7.13% |
| Mar 31, 2022 | 38.62% |
| Dec 31, 2021 | -80.35% |
| Sep 30, 2021 | 74.12% |